Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Truncation in Survival Analysis

Truncation in Survival Analysis

Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are observed.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mitochondrial translocation of MDM2 and TFAM reprograms metabolism in treatment-refractory cancers.

NPJ precision oncology·2026

Same author

31<sup>st</sup> International Cell Death Society (ICDS) meeting: "Cell fate and its regulation in health and disease".

Cell communication and signaling : CCS·2026

Same author

CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies.

Journal of hematology & oncology·2026

Same author

Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024.

Cancer research·2025

Same author

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies.

Leukemia·2025

Same author

Trade-offs in microplastic-adsorbed iopamidol degradation by UV-AOPs: Molecular-level insights into deiodination pathways versus iodinated disinfection by-products formation.

Water research·2025

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Published on: July 7, 2023

TRAILing death in cancer.

Gregory Mellier¹, Sinong Huang, Kirthan Shenoy

¹Department of Physiology, Yong Loo Lin School of Medicine, Singapore.

Molecular Aspects of Medicine

|December 10, 2009

Summary

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy by targeting cancer cells. Overcoming TRAIL resistance is key to improving treatment outcomes.

Area of Science:

Oncology
Molecular Biology
Immunology

Background:

Cancer cells often express death receptors (DRs) on their surface, making them targets for novel anti-cancer therapies.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising molecule that selectively induces apoptosis in cancer cells by binding to DRs (TRAIL-R1/R2, DR4/DR5).
TRAIL-induced apoptosis involves both extrinsic and intrinsic pathways, regulated at multiple cellular levels.

Purpose of the Study:

To review the biology, function, and translational relevance of TRAIL in cancer therapy.
To discuss mechanisms of TRAIL resistance in cancer cells.
To explore strategies for overcoming TRAIL resistance to improve therapeutic efficacy.

Main Methods:

Literature review focusing on TRAIL biology, apoptosis pathways, and resistance mechanisms.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Published on: July 7, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Detecting Anastasis In Vivo by CaspaseTracker Biosensor

Published on: February 1, 2018

Analysis of current research trends in overcoming TRAIL resistance.

Evaluation of translational relevance and clinical implications.

Main Results:

TRAIL demonstrates tumor-selective apoptosis induction via death receptor ligation.
TRAIL-induced apoptosis is regulated at both cell surface and intracellular levels.
Cancer cells can develop resistance to TRAIL, posing a significant therapeutic challenge.

Conclusions:

Understanding TRAIL resistance mechanisms is crucial for effective cancer treatment.
Developing strategies to overcome TRAIL resistance is essential for improving clinical outcomes.
TRAIL-based therapies hold significant potential if resistance issues are addressed.